Yuheng Pharmaceutical (002437.SZ) released semi-annual results, with net profit of 159 million yuan to mother, an increase of 18.27% over the previous year

According to Zhitong Finance App, Yuheng Pharmaceutical (002437.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,007 billion yuan, a year-on-year decrease of 8.41%; net profit attributable to shareholders of listed companies was 159 million yuan, an increase of 18.27% over the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 130 million yuan, an increase of 22.24% over the same period last year; basic earnings per share were 0.0724 yuan.

During the reporting period, the company further promoted the reform of the marketing system, completed the optimization of the organizational structure of the marketing center, established a new innovative medical division and formed a specialized team to consolidate the organizational foundation for the commercialization and business transformation of pre-filled methotrexate injections. By integrating sales channels and deepening the market network, the company's competitive advantage of core products was consolidated: in the first half of 2026, sales of injectable multivitamin (12) continued to rise, with a year-on-year increase of more than 10%; sales of quercus peptides increased nearly 15% year over year. According to rice intranet data, the market share of this product increased to 65.5% in the first quarter of 2026; Annuol/tablets covered more than 4,600 hospitals, and sales increased by more than 3% year on year. Among them, sales exceeded 100,000 boxes through e-commerce platforms; the market share of potassium chloride slow-release tablets increased further. According to data from MiIntranet for the first quarter of 2026, the market share of this product in urban public and county-level public hospitals increased to 29.21%. According to data from Zhongkang for the first quarter of 2026, the product's share of the retail market in pharmacies nationwide increased to 61.8%.

At the same time, the company is focusing on cultivating a second growth curve. The sales growth rate of non-core varieties is obvious: sales of injectable papaverine hydrochloride increased 153.17% year on year, sales of injectable cyclophosphamide increased 133.15% year on year, sales of sitagliptin metformin sustained-release tablets increased 69.67% year on year, and sales of sodium hyrate injections increased 15.82% year on year. During the reporting period, the revenue achieved by the above four products accounted for more than 8% of operating income.